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ABSTRACT  
 
Amyotrophic lateral sclerosis is an adult-onset neurodegenerative disease that develops due 
to motor neuron death. Several mechanisms occur supporting neurodegeneration, including 
mitochondrial dysfunction. Recently, we demonstrated that the synaptosomes from the spinal 
cord of SOD1
G93A
 mice, an in vitro model of presynapses, displayed impaired mitochondrial 
metabolism at early pre-symptomatic stages of the disease, while perisynaptic astrocyte 
particles, or gliosomes, were characterized by mild energy impairment only at symptomatic 
stages. This work aimed to understand whether mitochondrial impairment is a consequence 
of upstream metabolic damage. We analysed the critical pathways involved in glucose 
catabolism at presynaptic and perisynaptic compartments. 
Spinal cord and motor cortex synaptosomes from SOD1
G93A
 mice displayed high activity of 
hexokinase and phosphofructokinase, key glycolysis enzymes, and of citrate synthase and 
malate dehydrogenase, key Krebs cycle enzymes, but did not display high lactate 
dehydrogenase activity, the key enzyme in lactate fermentation. This enhancement was 
evident in the spinal cord from the early stages of the disease and in the motor cortex at only 
symptomatic stages. Conversely, an increase in glycolysis and lactate fermentation activity, 
but not Krebs cycle activity, was observed in gliosomes from the spinal cord and motor 
cortex of SOD1
G93A
 mice although only at the symptomatic stages of the disease. The cited 
enzymatic activities were enhanced in spinal cord and motor cortex homogenates, paralleling 
the time-course of the effect observed in synaptosomes and gliosomes. 
The observed metabolic modifications might be considered an attempt to restore altered 
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INTRODUCTION 
 
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease that results 
in muscle weakness and spasticity due to the selective and progressive degeneration of 
cortical, brainstem and spinal motor neurons (MNs) (Eisen 2009; Brown and Al-Chalabi 
2017). The death of patients with ALS often happens as a result of respiratory failure that 
usually occurs within 3-5 years after diagnosis (Rowland and Shneider 2001; Turner et al. 
2013). ALS may develop in two different forms, sporadic (sALS) and familial (fALS); the 
latter form represents 5-10% of the whole patient population (Swinnen and Robberecht 
2014). Even though over 120 potential genes have been identified as possible causes of ALS 
(Vandoorne et al. 2018), approximately 25% of the total fALS cases are associated with 
mutations in the gene that encodes Cu/Zn superoxide dismutase type 1 (SOD1). More than 
100 distinct SOD1 mutations have been identified (Kaur et al. 2016), and one of the most 
abundant SOD1 mutations is the substitution of the glycine at position 93 with alanine 
(G93A), that was the firstly characterized SOD1 mutation linked to ALS (Gurney et al. 
1994). For this reason, mice that express the SOD1
G93A
 mutation are currently the most 
common animal model used to study human ALS (Philips and Rothstein 2015).  
At present, only two drugs are available: riluzole and edavarone. The first drug increases the 
survival of patients by a few months, but there is no clear evidence that it ameliorates quality 
of life (Lu et al. 2016), and the second drug is only effective in patients suffering from early-
stage ALS (Abe et al. 2017); thus, the need for more efficacious therapies is urgent. 
However, ALS is a very heterogeneous disorder, with many biological alterations that occur, 
often concomitantly, during disease progression, making it difficult to find a cure. These 
biological alterations include glutamate-mediated excitotoxicity, oxidative stress, protein 
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dysregulated RNA signalling, immunological imbalance, and environmental stress response 
(Callaghan et al. 2011; Ferraiuolo et al. 2011; King et al. 2016; Peters et al. 2015; Tan et al. 
2014; Lysogorskaia et al. 2012; Van Den Bosch et al. 2006). 
In particular, mitochondrial dysfunction and energy production impairment have been 
proposed as two of the molecular mechanisms that explain MN degeneration (Vandoorne et 
al. 2018; Carrì et al. 2015; Tan et al. 2014). In fact, alterations in oxidative phosphorylation 
(OxPhos) metabolism have been observed both in mouse models and in patients (Mattiazzi et 
al. 2002; Kawamata and Manfredi 2010; Ferri et al. 2008; Cozzolino et al. 2009), as well as 
before the clinical onset of ALS pathology (Browne et al. 2006). Metabolic alterations have 
been described both in brain and spinal cord cells (Wiedemann et al. 2002; Borthwick et al. 
1999) as well as in skeletal muscle and liver (Martin 2011), in which the activity of the 
respiratory electron transport chain and relative ATP synthesis are impaired. Moreover, 
mitochondrial fusion and fission processes appeared dysfunctional, increasing the damage to 
energy production (Sasaki and Iwata 1999; Menzies et al. 2002a; Jiang et al. 2015). 
Although MNs are considered the principal target in ALS, astrocytes, microglia, and 
oligodendrocytes are also involved in the etiopathogenesis of ALS, suggesting that ALS is a 
non-cell autonomous disease (Ilieva et al. 2009; Haidet-Phillips et al. 2011). The bioenergetic 
interactions between astrocytes and the neighbouring MNs are altered in ALS (Allen and 
Barres 2005; Bilsland et al. 2008), and SOD1
G93A
 mouse-derived astrocytes can induce 
defects in the mitochondria of MNs and reduce neuronal survival (Nagai et al. 2007; Bilsland 
et al. 2008; Cassina et al. 2008). In addition, in vitro studies showed that mitochondrial 
dysfunction in astrocytes is associated with free radical production and release, which 
contribute to MN dysfunction in the SOD1
G93A
 mouse model of ALS (Cassina et al. 2008; 
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 mice, an impairment of the enzymatic activities involved 
in glycolysis and the Krebs cycle has been observed (Palamiuc et al. 2015; Tefera et al. 
2016). This dysfunction is associated with a decrease in glucose uptake in numerous brain 
regions and in the spinal cord of animal models and patients with ALS (Miyazaki et al. 
2012). Additionally, astrocytes also show decreased lactate release in ALS models compared 
with control conditions, probably due to altered gene expression of the astrocytic lactate 
efflux transporter, which contributes to MN degeneration (Ferraiuolo et al. 2011). Astrocytes 
are also considered a key component of the synapse domain due to their essential role in 
regulating synaptic function, strength and plasticity. Indeed, astrocytes form a well-structured 
anatomic and functional assembly with the presynaptic and postsynaptic neuronal bodies of 
the synapse, leading to the widely accepted concept of a tripartite synapse (Perea et al. 2009; 
Papouin et al. 2017).  
Recently, we demonstrated the presence of alterations in OxPhos metabolism with an in vitro 
model of presynaptic axon terminals and perisynaptic astrocyte processes in SOD1
G93A
 mice. 
In particular, we observed that mitochondrial energy production was differentially impaired 
in spinal cord axon terminals and perisynaptic astrocyte processes during disease progression, 
supporting the idea that these two regions may differentially contribute to synaptic damage in 
ALS (Ravera et al. 2018). On the basis of our previous work, in the current study we obtained 
original data describing the activity of some key enzymes in glycolysis, the Krebs cycle and 
lactate fermentation (schematically reported in Figure 1) in different synaptic regions, i.e., the 
presynaptic compartments of neurons and the perisynaptic compartments of astrocytes, to 
understand whether the observed mitochondrial impairment is a consequence of upstream 
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MATERIALS AND METHODS 
 
Reagents 
All reagents are identified by the catalogue number and the year of purchase. 
Salts, substrates, and all other chemicals of analytical grade were purchased from Sigma-
Aldrich/Merck (St. Louis, MO, USA), including sucrose (Cat# 84097/2017), Tris-HCl (Cat# 
T3253/2017), Percoll (Cat# P1644/2017), bovine serum albumin (BSA); Cat# 05470/2017), 
MgCl2 (Cat# M8266/2016), glucose (Cat# G7528/2016), ATP (Cat# A2383/2017), NADP 
(Cat# N5755/2017), glucose-6-phosphatase dehydrogenase (G6PD); Cat# G5760/2017), KCl 
(Cat# P9333/2016), fructose 6-phosphate (Cat# F3627/2017), phosphoenolpyruvate (PEP); 
Cat# P0564/2017), NADH (Cat# N8129/2017), pyruvate kinase (PK); lactate dehydrogenase 
(LDH) mix (Cat# P0294/2017), pyruvate (Cat# P8574/2017), oxaloacetic acid (Cat# 
O7753/2017), and acetyl CoA (Cat# A2056/2017). 
Ultrapure water (Milli-Q; Millipore, Billerica, MA, USA) was used throughout this study. 
Safety precautions were taken for chemical hazards in carrying out the experiments. 
 
Animals 
B6SJL-TgN SOD1/G93A(+)1Gur mice expressing a high copy number of mutant human 




; RRID: MGI:4829804) and B6SJL-TgN 
(SOD1)2Gur mice expressing wild-type human SOD1 (wtSOD1; Jackson Cat# 002297/2017) 
(Gurney et al. 1994) were originally obtained from Jackson Laboratories (Bar Harbor, ME) 
and bred at the animal facility of the Pharmacology and Toxicology Unit, Department of 
Pharmacy in Genoa. Transgenic animals were crossed with background-matched B6SJL 
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in the hemizygous state. All transgenic mice were identified by analysing tissue extracts from 
tail tips as previously described (Bonifacino et al. 2017). Tissue was homogenized in 
phosphate-buffered saline (PBS), freeze/thawed twice and centrifuged at 23,000 x g for 15 
min at 4°C, and human SOD1 was evaluated by staining for its enzymatic activity after 10% 
non-denaturing polyacrylamide gel electrophoresis. Animals were housed (6/7 per cage) at 
constant temperature (22 ± 1°C) and relative humidity (50%) with a regular 12 h-12 h light 
cycle (light 7 AM-7 PM) throughout the experiments. Food (4RF21 standard diet obtained 
from Mucedola, Settimo Milanese, Milan, Italy; Cat# 4RF21/2018) and water were freely 
available. The number of animals of each sex was balanced in each experimental group to 
avoid bias due to intrinsic sex-related differences. For experimental use, animals were 
sacrificed at different stages of disease, according to their age (30, 60, 90, and 120 days old). 
Experiments were carried out in accordance with the guidelines established by the European 
Communities Council (EU Directive 114 2010/63/EU for animal experiments published on 
September 22
nd
, 2010) and the Italian D.L. n. 26/2014 and were approved by the local Ethical 
Committee and by the Italian Ministry of Health (Project Authorization No.97/2017-PR). All 
efforts were made to minimize animal suffering and to use only the number of animals 
necessary to produce reliable results. All the experiments complied with the ARRIVE 
guidelines. A total of 22 wtSOD1 and 20 SOD1
G93A
 mice were utilized in this study. No 
blinding procedures were applied in the experiments. 
 
Purification of synaptosomes and gliosomes 
wtSOD1 and SOD1
G93A 
mice (30, 60, 90, and 120 days old) were euthanized by cervical 
dislocation, without prior anaesthesia by personnel well-trained with this technique, and the 
motor cortex and spinal cord were rapidly removed. Synaptosomes and gliosomes were 
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homogenized in 0.32 M sucrose, buffered at pH 7.4 with Tris-HCl, using a glass-Teflon 
tissue grinder (clearance 0.25 mm - Potter-Elvehjem VWR International). The homogenate 
was centrifuged (5 min, 1,000 x g) to remove nuclei and debris. The supernatant was 
harvested and centrifuged at 12,000 x g for 10 min, and the pellet was suspended in Tris-
buffered 0.32 M sucrose and gently layered on a discontinuous Percoll
®
 gradient (2, 6, 10 and 
20% v/v in Tris-buffered 0.32 M sucrose). After centrifugation at 33,500 x g for 5 min, the 
layer between 2 and 6% (gliosomal fraction) and between 10 and 20% (synaptosomal 
fraction) Percoll
® 
were collected and washed by centrifugation at 20,000 x g for 15 min with 
PBS. Gliosomal and synaptosomal pellets were suspended in PBS. All of the above 
procedures were conducted at 4°C. Protein content was measured according to the Bradford 
assay (Bradford 1976), using BSA as a standard. Enzymatic assays for each set of data were 
performed only after all samples were collected, allowing for the reaction mixture preparation 
of the assays to be optimized and avoiding variability due to the preparation of different 
reaction mixtures. 
 
Confocal microscopy experiments 
Purified synaptosomes or gliosomes (40 µg of total protein) obtained from the motor cortex 
and spinal cord of 30, 60, 90, and 120-day-old SOD1
G93A 
and age-matched wtSOD1 mice 
were stratified onto poly-L-lysine pre-treated coverslips and maintained for 45 min at room 
temperature to allow the samples to settle and stick to the surface. The samples were fixed 
with 2% paraformaldehyde (15 min), washed with PBS (3x5 min) and permeabilized (5 min) 
with 0.05% Triton X-100. After washing (3x5 min) with PBS containing 0.5% BSA, the 
synaptosomes and gliosomes were triple-labelled by an overnight incubation at 4 °C with 
primary antibodies diluted in PBS containing 3% BSA. The following primary antibodies 
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Cat# M1406/2018; RRID: AB_477171); rabbit anti-glial fibrillary acidic protein (GFAP; 
1:1000, Sigma-Aldrich, Cat# G4546/2018: RRID: AB_1840895); and goat anti-LDH 
(1:1000, Chemicon International, Cat# AB1222/2018, RRID:AB_90491). After washing (3x5 
min) with PBS containing 0.5% BSA, the synaptosomes and gliosomes were then incubated 
for 45 min at room temperature with the appropriate secondary antibodies. The following 
secondary antibodies were used: goat anti-rabbit Alexa Fluor A555-conjugated 
(ThermoFisher Scientific, Cat# A-21428/2017, RRID:AB_2535849); donkey anti-mouse 
Alexa Fluor A488-conjugated (ThermoFisher Scientific, Cat# A-21202/2017, 
RRID:AB_141607); donkey anti-goat Alexa Fluor A647-conjugated (ThermoFisher 
Scientific, Cat# A-21447/2018, RRID:AB_2535864). Antibodies were diluted 1:2000 in PBS 
containing 3% BSA. Fluorescence image (512 x 512 x 8 bit) acquisition was performed by a 
three-channel Leica TCS SP5 laser-scanning confocal microscope equipped with 458, 476, 
488, 514, 543 and 633 nm excitation lines through a plan-apochromatic oil immersion 
objective 63x/1.4. Light collection was optimized according to the combination of the chosen 
fluorochromes, and sequential channel acquisition was performed to avoid cross-talk. The 
Leica “LAS AF” software package was used for image acquisition. The quantitative analyses 
of co-localization and the relative protein expression level were performed by calculating co-
localization coefficients (Manders et al. 1992). 
Glycolytic enzyme assays 
Hexokinase (HK; EC 2.7.1.1) and phosphofructokinase (PFK; EC 2.7.1.11) were assayed as 
markers of the glycolysis pathway at room temperature using 20 µg of the total protein from 
synaptosomes, gliosomes, or tissue homogenate in a double beam spectrophotometer 
(UNICAM UV2, Analytical S.n.c., Italy). Enzymatic activity was expressed as international 
milliunits/mg (mIU/mg), corresponding to the nanomoles of substrate converted in 1 min. 
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pH 7.4, 5 mM MgCl2, 200 mM glucose, 1 mM ATP, 0.91 mM NADP, and 0.55 IU/ml of 







 at 340 nm); and PFK, 100 mM Tris-HCl at pH 7.4, 2 mM MgCl2, 5 
mM KCl, 2 mM fructose 6-phosphate, 1 mM ATP, 0.5 mM PEP, 0.2 mM NADH, 2 IU/ml 







 at 340 nm). HK and PFK were chosen as markers of the glycolytic pathway because 
they catalyse two irreversible reactions that are distinct from gluconeogenesis, which 
represents the counterpart of glycolysis. Moreover, HK and PFK are two regulatory points of 
glycolysis (Berg et al. 2002a). 
 
Lactate fermentation assay 
LDH (EC 1.1.1.27) was assayed as a marker of lactate fermentation. The reaction mixture 
contained 100 mM Tris-HCl at pH 7.4, 5 mM pyruvate and 0.2 mM NADH (NADH molar 






 at 340 nm). Enzymatic 
activity was expressed as mIU/mg, LDH was chosen as a marker of lactate fermentation 
because it is the unique enzyme responsible for the conversion of pyruvate to lactate, the final 
step of anaerobic glycolysis (Berg et al. 2002b). 
 
Krebs cycle enzyme assay 
Citrate synthase (CS; EC 4.1.3.7) and malate dehydrogenase (MDH; EC 1.1.1.37) were 
assayed as markers of the Krebs cycle in 20 µg of the total protein from synaptosomes and 
gliosomes using a double beam spectrophotometer (UNICAM UV2, Analytical S.n.c., Italy) 
at room temperature. Enzymatic activity was expressed as mIU/mg. The following reaction 
mixtures were used (Ravera et al. 2013): CS, 100 mM Tris-HCl at pH 8, 0.17 mM 

















, at 232 nm); MDH, 100 mM Tris-HCl at pH 7.5, 0.5 mM oxaloacetic acid, and 0.2 







340 nm). CS was chosen as a marker of the Krebs cycle because it is considered to be the 
regulator of Krebs cycle rate and is inhibited by high concentrations of ATP, acetyl CoA, and 
NADH, which indicate a high level of energy supply (Krebs 1970). MDH was chosen as the 
second marker of Krebs cycle functionality because it interacts with the cytochrome bc1 
complex and therefore represents an interaction between citric acid cycle enzymes and 
electron transfer chain complexes, playing a regulatory role in mitochondrial bioenergetics 
(Wang et al. 2010). 
 
Statistics 
Data are expressed as the mean ± s.e.m., and p value < 0.05 was considered significant. The 
normality of the data was verified by the Kolmogorov-Smirnov test. The presence of outliers 
was determined by the Grubbs' test and no data were excluded. Sample size calculations were 
not performed. Multiple comparisons were performed using analysis of variance (two-way 
ANOVA) followed by Bonferroni post hoc test. Sigma Stat (Sigma Stat Software, Inc., San 
Jose, CA, USA, USA, version 3.5 (2006), registration number 773050002 
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RESULTS 
 
Purity of the synaptosomes and gliosomes preparations isolated from wtSOD1 and 
SOD1
G93A
 mouse spinal cord and motor cortex 
To verify whether the purity of the neuronal and glial preparations could change in SOD1
G93A
 
mice at different stages of the disease, we performed laser confocal microscopy experiments. 
Synaptosomes and gliosomes were prepared from mouse spinal cord and motor cortex tissues 
of 30-, 60-, 90-, and 120-day-old SOD1
G93A
 and wtSOD1 mice by homogenization and 
purification on a discontinuous Percoll gradient and were immunolabelled with antibodies 
against MAP2, a selective neuronal marker, anti-GFAP, a selective astrocyte marker, and 
anti-LDH. Because LDH is a cytosol-localized enzyme, it can be assumed that LDH-positive 
particles represent re-sealed synaptosomes or gliosomes rather than membrane debris. 
Spinal cord synaptosomes were efficiently stained for LDH and MAP2, and gliosomes were 
stained for LDH and GFAP. Figure 2, Panel A shows representative images of spinal cord 
synaptosomes, and Figure 2, Panel B shows representative images of spinal cord gliosomes 
purified from 90-day-old SOD1
G93A
 and wtSOD1 mice. The merged images revealed that the 
majority (approximately 80%) of the LDH-positive particles were also MAP2-positive in 
synaptosomes and GFAP-positive in gliosomes. Figure 2, Panels C and D report the 
quantification of the LDH particles that were also positive for MAP2 or GFAP in 
synaptosomes or gliosomes, respectively, at the different stages of the disease. No significant 
differences in the expression of the MAP2 neuronal component or the GFAP-positive 
contaminating glia component were detected in the synaptosomal samples of SOD1
G93A
 and 
wtSOD1 mice at any disease stages. The same was true for GFAP expression and for MAP2-
labelled neuronal contamination in gliosomes. Additionally, motor cortex synaptosomes were 
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and GFAP (Figure 3, Panels A and B for representative images of synaptosomes and 
gliosomes, respectively, purified from 90-day-old wtSOD1 or SOD1
G93A
 mice). GFAP 
contamination in synaptosomes and MAP2 contamination in gliosomes were less than 20%. 
Figure 3, Panels C and D report the quantification of synaptosome and gliosome purity and 
show that no significant differences in MAP2 and GFAP expression were detected in the 
synaptosomes or gliosomes of SOD1
G93A
 and wtSOD1 mice at any disease stage. 
Thus, disease progression does not modify the degree of purification of synaptosomes and 
gliosomes from the spinal cord and motor cortex, allowing for the direct comparison of the 




Krebs cycle activity in synaptosomes and gliosomes isolated from wtSOD1 and 
SOD1
G93A
 mouse spinal cord 
To investigate whether the dysfunctional mitochondrial metabolism previously observed in 
synaptosomes isolated from SOD1
G93A
 mouse spinal cord (Ravera et al. 2018) depends on an 
upstream alteration of the Krebs cycle, we evaluated the activity of CS and MDH in spinal 
cord homogenates and derived synaptosomes and gliosomes obtained from SOD1
G93A 
and 
wtSOD1 mice. Synaptosomes displayed a significantly increased activities of both enzymes at 
the early stage of the pathology in SOD1
G93A
 mice compared with wtSOD1 mice (CS: 
p<0.001, F(3,1,3,16)=52.138 at 30, 60, 90 and 120 days of age; MDH: p<0.001, F(3,1,3,16)=17.588 
at 30, 60, 90 and 120 days of age) (Figure 4, Panels A and D). Conversely, in gliosomes, 
which did not exhibit altered OxPhos metabolism (Ravera et al. 2018), the activities of CS 
and MDH in samples from SOD1
G93A 
mice were similar to those of control samples (Figure 4 
Panels B and E). The evaluation of CS and MDH activity in the spinal cord homogenate 
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days of age (for CS: p<0.001, F(3,1,3,16)=8.375 at 30, 60, 90 and 120 days of age; for MDH: 
p<0.001, F(3,1,3,16)=28.867 at 30, 60, 90 and 120 days of age) (Figure 4 Panels C and F). 
Thus, Krebs cycle activity was strongly and precociously increased in spinal cord tissue and 
derived nerve terminals but not in perisynaptic astrocyte gliosomes in SOD1
G93A 
mice 
compared with wtSOD1 mice. 
 
Glycolysis activity in synaptosomes and gliosomes isolated from wtSOD1 and SOD1
G93A
 
mouse spinal cord 
Considering the enhanced Krebs cycle activity (present results) and the high glucose 
consumption in ALS (Valbuena et al. 2017), we also evaluated glycolytic flux by analysing 
the activity of HK and PFK in spinal cord homogenates and derived synaptosomes and 
gliosomes obtained from SOD1
G93A 
and wtSOD1 mice. 
Compared to controls, both SOD1
G93A
 spinal cord synaptosomes (Figure 5, Panels A and D) 
and homogenate (Figure 5, Panels C and F) showed a significant increase in HK and PFK 
activity as early as 30 days of age (HK in synaptosomes: p<0.001, F(3,1,3,16)= 58.040 at 30, 60, 
90 and 120 days; HK in homogenate: p<0.001, F(3,1,3,16)= 380.458 at 30, 60, 90 and 120 days; 
PFK in synaptosomes: p<0.001, F(3,1,3,16)= 32.976 at 30, 60, 90 and 120 days; PFK in 
homogenate: p<0.001, F(3,1,3,16)= 47.574 at 30, 60, 90 and 120 days). A significant 
enhancement in the activity of glycolytic enzymes was also observed in gliosomes from the 
spinal cord of SOD1
G93A 
mice compared with those of wtSOD1 mice (Figure 5, Panels B and 
E), but only at 90 and 120 days of age (HK: p<0.001, F(3,1,3,16)= 9.264 at 90 and 120 days; 
PFK: p<0.001, F(3,1,3,16)= 40.418 at 90 and 120 days). 
Thus, glycolytic flux was increased in the spinal cord tissue and in the derived synaptosomes 
and gliosomes of SOD1
G93A 
mice compared with those of control mice; however, in 
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Lactate fermentation in synaptosomes and gliosomes isolated from wtSOD1 and 
SOD1
G93A
 mouse spinal cord 
Since pyruvate, derived from glycolysis, can be converted either to acetyl CoA (the initial 
substrate of the Krebs cycle) or to lactate (the final product of lactate fermentation), we also 
evaluated the activity of LDH in the spinal cord homogenate and derived synaptosomes and 
gliosomes obtained from SOD1
G93A 
and wtSOD1 mice. As reported in Figure 6, the LDH 
activity of SOD1
G93A
 synaptosomes was similar to that of wtSOD1 synaptosomes (Panel A). 
In contrast, the spinal cord gliosomes and homogenate of SOD1
G93A
 mice displayed 
significantly increased LDH activity compared with those of wtSOD1 mice (Panels B and C, 
respectively). In particular, this enhancement was evident in gliosomes at 90 and 120 days of 
age (p<0.001, F(3,1,3,16)= 131.805 at 90 and 120 days), while in spinal cord homogenate, this 
enhancement was observed at 60 days of age (p<0.001, F(3,1,3,16)= 233.472 at 60, 90 and 120 
days). 
Thus, the lactate fermentation rates of SOD1
G93A
 mice were increased in spinal cord 
gliosomes, and precociously increased in the homogenate but not increased in synaptosomes 
compared with those of wtSOD1 mice. 
 
Krebs cycle activity in synaptosomes and gliosomes isolated from wtSOD1 and 
SOD1
G93A
 mouse motor cortex 
ALS progression also involves upper MN damage in the motor cortex. Therefore, we 
evaluated the activity of CS and MDH, as markers of Krebs cycle efficiency, in this tissue 
and in synaptosomes and gliosomes derived from SOD1
G93A
 and wtSOD1 mice. Figure 7 
shows that the motor cortex synaptosomes (Panels A and D) and homogenate (Panels C and 
F) from SOD1
G93A
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compared with those from wtSOD1 mice (CS synaptosomes: p<0.001, F(3,1,3,16)= 17.588 at 90 
and 120 days; CS homogenate: p<0.001, F(3,1,3,16)= 28.867 at 90 and 120 days; MDH 
synaptosomes: p<0.001, F(3,1,3,16)= 242.607 at 90 and 120 days; PFK homogenate: p<0.001, 
F(3,1,3,16)= 21.536 at 90 and 120 days). Conversely, the gliosomes from the SOD1
G93A
 and 
wtSOD1 mice did not show any differences (Panels B and E). 
Thus, as observed in the spinal cord, CS and MDH activities increase in motor cortex 
synaptosomes and homogenate, starting at the symptomatic phase of the disease. Gliosomes 
do not show these alterations. 
 




Figure 8 shows the activity of HK and PFK in motor cortex synaptosomes and gliosomes and 
in the homogenate from SOD1
G93A
 and wtSOD1 mice. The synaptosomes (Panels A, D), 
gliosomes (Panels B, E) and tissue homogenate (Panels C, F) from SOD1
G93A
 mice displayed 
significantly increased HK and PFK activities compared with those from wtSOD1 mice. 
Specifically, gliosomes showed a significant increase in glycolytic rate only at the 
symptomatic stages of the disease, as in spinal cord (HK p<0.001, F (3,1,3,16)= 7.014 at 90 and 
120 days; PFK p<0.001, F(3,1,3,16)= 61.899 at 90 and 120 days). Additionally, synaptosomes 
and homogenate showed a significant increase in HK and PFK activities at 90 and 120 days, 
while in the spinal cord, the increase was significant at 30 days of age (see Figure 5) (HK 
synaptosomes: p<0.001, F(3,1,3,16)= 47.830 at 90 and 120 days; HK homogenate: p<0.001, 
F(3,1,3,16)= 11.673 at 90 and 120 days; PFK synaptosomes: p<0.001, F(3,1,3,16)= 29.871 at 90 
and 120 days; PFK homogenate: p<0.001, F(3,1,3,16)= 43.262 at 90 and 120 days). 
Thus, the glycolytic rate was also increased in the motor cortex of SOD1
G93A
 mice compared 
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Lactate fermentation in synaptosomes and gliosomes isolated from wtSOD1 and 
SOD1
G93A
 motor cortex 
Figure 9 reports the activity of LDH, a marker of lactate fermentation, in motor cortex 
synaptosomes and gliosomes and in homogenate from SOD1
G93A
 and wtSOD1 mice. 
Synaptosomes from SOD1
G93A
 mice were similar to those from wtSOD1 mice (Panel A). In 
contrast, the gliosomes and homogenate of SOD1
G93A
 mice displayed significantly increased 
LDH activity at 90 and 120 days of age compared with those of wtSOD1 mice (Panels B and 
C) (gliosomes p<0.001, F(3,1,3,16)= 58.716 at 90 and 120 days of age; homogenate p<0.001, 
F(3,1,3,16)= 46.575 at 90 and 120 days of age). 
Thus, the lactate fermentation rate appeared to be increased in the motor cortex gliosomes 
and homogenate, but not the synaptosomes, of wtSOD1 mice compared with those of 




The data reported herein represent the first study addressing glucose catabolism in 
synaptosomes, presynaptic axon terminals, and gliosomes, perisynaptic astrocyte processes, 
derived from the spinal cord and motor cortex of SOD1
G93A
 mice, a widely studied animal 
model of ALS. Although impaired energy metabolism has already been described in ALS 
(Menzies et al. 2002b; Tan et al. 2014; Sasaki and Iwata 2007), much less is known about the 
distinctive contribution of neurons and glia at the synaptic level. 
We focused our attention on the presynaptic and perisynaptic regions on the basis of our 
previous studies that supported the idea that ALS can be considered a synaptopathy. In fact, 
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mice compared with control mice, starting from the early pre-symptomatic stage of the 
disease, and this effect is sustained by plastic changes in key protein pathways that regulate 
neurotransmitter release at the nerve terminal level (Milanese et al. 2011; Bonifacino et al. 
2016). Due to the well-documented non-cell autonomous disease features of ALS, which also 
involve non-neuronal cell, such as astrocytes (Ilieva et al. 2009; Haidet-Phillips et al. 2011), 
contributing to MN degeneration, we thought that the bioenergetic failures that occur during 
disease progression not only at the nerve terminal level but also at the astrocyte perisynaptic 
moieties, which surely influence synaptic function, were worthy of analysis (Perea et al. 
2009; Papouin et al. 2017). 
Synaptosomes and gliosomes represent a unique tool to investigate the bioenergetic signature 
of the presynaptic and perisynaptic compartments of the tripartite synapse and to reveal 
changes during the progression of ALS, since these components can be freshly prepared from 
mouse spinal cord and motor cortex at different stages of the disease. Synaptosomes represent 
the site of neurotransmitter release and retain most of the characteristics of the nerve 
terminals in vivo, including the presence of functional mitochondria that meet their 
bioenergetic needs (Raiteri 1983; Whittaker 1993; Ghijsen et al. 2003). Gliosomes are a 
subcellular preparation that originate from astrocytes (Stigliani et al. 2006) and that possess 
the biochemical and functional characteristics of the cells from which they are derived 
(Nakamura et al. 1993; Stigliani et al. 2006; Paluzzi et al. 2007). Remarkably, gliosomes 
express proteins involved in the release machinery and vesicles competent for gliotransmitter 
exocytosis, as well as transmitter receptors and transporters to interact with the neuronal 
counterparts. Thus, gliosomes are likely representative of the astrocytic regions that surround 
the synapses, since they are enriched in proteins distinctive of the perisynaptic astrocytic 
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Given that ALS in SOD1
G93A 
mice is characterized by major synaptic structural changes 
during disease progression and to exclude that these changes could have influenced the 
efficiency of the purification of synaptosomes and gliosomes and, in turn, affected the 
metabolic differences observed, we performed confocal microscopy experiments to 
characterize the purity of spinal cord and motor cortex synaptosomes and gliosomes from 
wtSOD1 and SOD1
G93A
 mice at the different stages of the disease. Both neuronal and glial 
particles showed a good grade of purification, confirming results previously found in the 
same or different brain regions of rat and mouse (Milanese et al. 2010; Raiteri et al. 2008; 
Paluzzi et al. 2007; Stigliani et al. 2006). Most importantly, these data demonstrate that there 
were no differences in the purity of samples during disease progression. This observation 
allows us to conclude that the differences in glucose metabolism described here were indeed 
due to intrinsic changes in neurons and glial cells. 
In a recent work (Ravera et al. 2018), we demonstrated that mitochondrial metabolism, in 
terms of OxPhos activity and coupling, is impaired in synaptosomes derived from the spinal 
cord of SOD1
G93A 
mice, indicating a decreases in their energetic capacity, starting at the early 
pre-symptomatic stages of the disease (30 days of age). Conversely, gliosomes show only a 
mild reduction in energy capacity and an increase in lipid peroxidation at the symptomatic 
stages, but do not show impaired mitochondrial metabolism (Ravera et al. 2018). Here, we 
evaluated the activity of some enzymes involved in glycolysis, Krebs cycle and lactate 
fermentation in synaptosomes and gliosomes derived from the spinal cord and motor cortex 
of SOD1
G93A
 mice, with the aim to investigate whether the mitochondrial dysfunction of 
synaptosomes and the involvement of gliosomes in altered energy metabolism may depend 
on an impairment of the upstream glucose catabolism. We selected these metabolic pathways 
because the Krebs cycle represents the principal source of the reduced coenzymes necessary 
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and produces pyruvate, which represents the crossroads between aerobic and anaerobic 
metabolism. Moreover, lactate fermentation is necessary for the production of lactate, one of 
the main fuels of the CNS (Fillenz 2005; Mason 2017). The above analyses were also 
extended to motor cortex and spinal cord tissue homogenates. 
The Krebs cycle activity assay showed that the activities of CS and MDH are increased in the 
synaptosomes derived from the spinal cord of SOD1
G93A
 mice compared with those from 
wtSOD1 mice beginning at the early stages of the disease, suggesting an attempt to increase 
the production of reduced coenzymes to enhance the impaired mitochondrial OxPhos activity. 
This increase of the aerobic metabolism also appeared to be favoured by the enhancement of 
the glycolysis pathway, as suggested by the increased HK and PFK activity. Interestingly, 
synaptosomes from the spinal cord of SOD1
G93A
 mice did not display an increase in LDH, 
indicating that the observed enhancement of glycolysis is completely devoted to aerobic 
metabolism. Conversely, the activity of the Krebs cycle in gliosomes derived from the spinal 
cord of SOD1
G93A
 was similar to that of control mice, while glycolysis and lactate 
fermentation were increased in SOD1
G93A
 compared with control mice, but exclusively at the 
symptomatic stages of the disease (90 and 120 days of age). These data suggest that 
synaptosomes and gliosomes show the same energy metabolism as their cellular counterparts 
(Bélanger et al. 2011), i.e., aerobic metabolism for neuron-derived synaptosomes and 
anaerobic metabolism for astrocyte-derived gliosomes. 
Moreover, the results reported herein are in accordance with our previous observation of a 
decrease in the ATP/AMP ratio in the same region (Ravera et al. 2018). The different 
alterations of synaptosome and gliosome metabolism suggest that the metabolic changes in 
ALS could be temporally different in tripartite synapses in situ, occurring first in the 
presynaptic and afterward in the perisynaptic regions. In other words, SOD1
G93A
 mouse 
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symptomatic stage of the disease, likely in response to an energy deficit already present at the 
nerve terminals in the early stages of the disease. However, the metabolic differences 
between synaptosomes and gliosomes also suggest the existence of two different pathological 
mechanisms in presynaptic and perisynaptic regions. 
The similarities between the time-course of the effect observed in synaptosomes and 
gliosomes and the effect observed in tissue homogenates suggest that these components may 
recapitulate changes taking place in the whole cells from which they are derived. Indeed, the 
activity of HK and PFK, representing glycolysis, and the activities of CS and MDH, 
representing the Krebs cycle, were increased at the early stages of the disease in both 
synaptosomes and tissue homogenates. Also, LDH activity was increased in gliosomes and 
homogenates; however, in the homogenate, this augmentation was evident already at 60 days, 
while in gliosomes, it increased only from 90 days. This apparent discrepancy may suggest 
that the activation of lactate fermentation occurs first in the astrocyte soma and subsequently 
in their processes. In both cases, the increase in lactate production, driven by augmented LDH 
activity, could be an attempt to provide additional energy support to neurons. 
Similar results were observed in motor cortex synaptosomes and gliosomes and in 
homogenate. However, in the motor cortex, the increase in metabolic activity was evident 
only at the symptomatic stages of the disease (90 and 120 days of age), both in synaptosomes 
and gliosomes and in the tissue homogenate, suggesting that the energetic damage in the 
motor cortex occurs after the damage to the spinal cord. Remarkably, in our previous work, 
no impaired energy status was observed in synaptosomes and gliosomes isolated from motor 
cortex (Ravera et al. 2018), further supporting the idea that in this brain region, the metabolic 
alterations may play a minor role, at least at the synaptic level. Interestingly, we previously 
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SOD1
G93A
 mice (Milanese et al., 2011), possibly indicating similarities between energetic 
impairment and alterations of glutamate transmission. 
Notably, the enhanced aerobic metabolism in synaptosomes induced by the production of 
reduced coenzymes through the Krebs cycle may pose a risk for a system in which 
mitochondria are dysfunctional. In fact, the accumulation of reduced coenzymes, due to the 
impairment of OxPhos machinery, can produce reductive stress, often associated with cell 
degeneration (Zhang et al. 2012). This event can be partially reversed by an increase in 
lactate fermentation, which converts NADH to NAD
+
.  On the other hand, the increase of 
glucose catabolism could represent an attempt to compensate for the OxPhos dysfunction.  
The literature regarding glucose catabolism in ALS appears conflicting. For instance, 
Szelechowski  et al have described an increase in the expression of Krebs cycle enzymes in 
MNs from SOD1
G93A
 mice compared with those from control mice, despite a reduction in 
OxPhos efficiency (Szelechowski et al. 2018), while Tefera and Borges observed a decrease 
in oxoglutarate dehydrogenase activity in brain cortex and spinal cord homogenates isolated 
from SOD1
G93A
 mice (Tefera et al. 2019), even though it was not associated with a decrement 
in the content of the Krebs cycle metabolites.  
Moreover, deficient glycolysis or Krebs cycle activity has been deeply investigated mainly in 
muscle homogenates obtained from different ALS murine models (Tefera et al. 2016; 
Palamiuc et al. 2015). Therefore, the different energy status results obtained in ALS could 
depend both on the different tissues and on the different targets investigated. In particular, the 
evaluation of metabolic intermediates is very difficult to interpret because the change in the 
content may depend on both the slowing down of the upstream reactions or the acceleration 
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In conclusion, our original data show an increment of the glucose catabolic pathways 
upstream the mitochondrial aerobic respiration in SOD1
G93A
 mice. This increment was 
present even at pre-symptomatic stages of the disease in spinal cord axon terminals; whereas, 
it was detectable only starting at symptomatic stages in motor cortex axon terminals and in 
astrocytic perisynaptic regions. The enhancement of glucose catabolism indicates that the 
impaired energy production in these districts (Ravera et al. 2018) is exclusively a 
consequence of mitochondrial dysfunction, implying that mitochondria represent the first site 
of the synaptic and possibly non-synaptic bioenergetic impairment in ALS. 
 
 
--Human subjects -- 
Involves human subjects: 
If yes: Informed consent & ethics approval achieved: 
=> if yes, please ensure that the info "Informed consent was achieved for all 
subjects, and the experiments were approved by the local ethics committee." is 
included in the Methods. 
 
ARRIVE guidelines have been followed: 
Yes 
=> if it is a Review or Editorial, skip complete sentence => if No, include a 
statement: "ARRIVE guidelines were not followed for the following reason: 
" 
(edit phrasing to form a complete sentence as necessary). 
=> if Yes, insert "All experiments were conducted in compliance with the 




The Authors are indebted to Mr. Giuseppe Marazzotta for his help in maintaining the 
SOD1
G93A
 mouse colonies. The authors gratefully acknowledge the undergraduate students 













This article is protected by copyright. All rights reserved. 
Funding 
This work was supported by research grants from the Italian Ministry of University (SIR 
project n. RBSI14B1Z) to MM and from the Motor Neurone Disease Association (project n. 
April16/848-791) to GB. 
 
Conflict of interest 
The authors declare no competing financial interests. 
 
REFERENCES 
Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., et al. (2017) Safety 
and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a 
randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505–512. 
Allen N. J., Barres B. A. (2005) Signaling between glia and neurons: focus on synaptic 
plasticity. Curr. Opin. Neurobiol. 15, 542–8. 
Bélanger M., Allaman I., Magistretti P. J. (2011) Brain Energy Metabolism: Focus on 
Astrocyte-Neuron Metabolic Cooperation. Cell Metab. 14, 724–738. 
Berg J., Tymoczko J., Stryer L. (2002a) The Glycolytic Pathway Is Tightly Controlled, in 
Biochem. 5th Ed., (W. H. Freeman and Company, ed). New York. 
Berg J., Tymoczko J., Stryer L. (2002b) Glycolysis Is an Energy-Conversion Pathway in 
Many Organisms., in Biochem. 5th Ed., (Company W. H. F., ed). New York. 
Bilsland L. G., Nirmalananthan N., Yip J., Greensmith L., Duchen M. R. (2008) Expression 
of mutant SOD1 
G93A
 in astrocytes induces functional deficits in motoneuron 
mitochondria. J. Neurochem. 107, 1271–1283. 










This article is protected by copyright. All rights reserved. 
(2017) In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the 
SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuropharmacology 123, 
433–445. 
Bonifacino T., Musazzi L., Milanese M., Seguini M., Marte A., Gallia E., Cattaneo L., Onofri 
F., Popoli M., Bonanno G. (2016) Altered mechanisms underlying the abnormal 
glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the 
disease. Neurobiol. Dis. 95, 122–133. 
Borthwick G. M., Johnson M. A., Ince P. G., Shaw P. J., Turnbull D. M. (1999) 
Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role 
of mitochondria in neuronal cell death. Ann. Neurol. 46, 787–90. 
Bosch L. Van Den, Damme P. Van, Bogaert E., Robberecht W. (2006) The role of 
excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. 
Acta - Mol. Basis Dis. 1762, 1068–1082. 
Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 
248–254. 
Brown R. H., Al-Chalabi A. (2017) Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 377, 
162–172. 
Browne S. E., Yang L., DiMauro J. P., Fuller S. W., Licata S. C., Beal M. F. (2006) 
Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord 
pathology in the G93A SOD1 mouse model of ALS. Neurobiol. Dis. 22, 599–610. 
Callaghan B., Feldman D., Gruis K., Feldman E. (2011) The association of exposure to lead, 










This article is protected by copyright. All rights reserved. 
epigenetic implications. Neurodegener. Dis. 8, 1–8. 
Carney K. E., Milanese M., Nierop P. Van, Li K. W., Oliet S. H. R., Smit A. B., Bonanno G., 
Verheijen M. H. G. (2014) Proteomic analysis of gliosomes from mouse brain: 
Identification and investigation of glial membrane proteins. J. Proteome Res. 13, 5918–
5927. 
Carrì M. T., Valle C., Bozzo F., Cozzolino M. (2015) Oxidative stress and mitochondrial 
damage: importance in non-SOD1 ALS. Front. Cell. Neurosci. 9, 41. 
Cassina P., Cassina A., Pehar M., Castellanos R., Gandelman M., Leon A. de, Robinson K. 
M., et al. (2008) Mitochondrial Dysfunction in SOD1G93A-Bearing Astrocytes 
Promotes Motor Neuron Degeneration: Prevention by Mitochondrial-Targeted 
Antioxidants. J. Neurosci. 28, 4115–4122. 
Cozzolino M., Pesaresi M. G., Amori I., Crosio C., Ferri A., Nencini M., Carrì M. T. (2009) 
Oligomerization of mutant SOD1 in mitochondria of motoneuronal cells drives 
mitochondrial damage and cell toxicity. Antioxid. Redox Signal. 11, 1547–58. 
Eisen A. (2009) Amyotrophic lateral sclerosis-Evolutionary and other perspectives. Muscle 
Nerve 40, 297–304. 
Ferraiuolo L., Kirby J., Grierson A. J., Sendtner M., Shaw P. J. (2011) Molecular pathways of 
motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7, 616–30. 
Ferri A., Nencini M., Cozzolino M., Carrara P., Moreno S., Carrì M. T. (2008) Inflammatory 
cytokines increase mitochondrial damage in motoneuronal cells expressing mutant 
SOD1. Neurobiol. Dis. 32, 454–60. 
Fillenz M. (2005) The role of lactate in brain metabolism. Neurochem Int 47, 413–417. 










This article is protected by copyright. All rights reserved. 
traffic and neurotransmitter release in isolated nerve terminals. Neurochem. Res. 28, 
1443–52. 
Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., 
Caliendo J., Hentati A., Kwon Y. W., Deng H. X. (1994) Motor neuron degeneration in 
mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772–5. 
Haidet-Phillips A. M., Hester M. E., Miranda C. J., Meyer K., Braun L., Frakes A., Song S., 
et al. (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor 
neurons. Nat. Biotechnol. 29, 824–828. 
Ilieva H., Polymenidou M., Cleveland D. W. (2009) Non?cell autonomous toxicity in 
neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187, 761–772. 
Jiang Z., Wang W., Perry G., Zhu X., Wang X. (2015) Mitochondrial dynamic abnormalities 
in amyotrophic lateral sclerosis. Transl. Neurodegener. 4, 14. 
Kaur S. J., McKeown S. R., Rashid S. (2016) Mutant SOD1 mediated pathogenesis of 
Amyotrophic Lateral Sclerosis. Gene 577, 109–18. 
Kawamata H., Manfredi G. (2010) Mitochondrial dysfunction and intracellular calcium 
dysregulation in ALS. Mech. Ageing Dev. 131, 517–526. 
King A. E., Woodhouse A., Kirkcaldie M. T. K., Vickers J. C. (2016) Excitotoxicity in ALS: 
Overstimulation, or overreaction? Exp. Neurol. 275, 162–171. 
Krebs H. A. (1970) Rate control of the tricarboxylic acid cycle. Adv. Enzyme Regul. 8, 335–
353. 
Lu H., Le W. D., Xie Y.-Y., Wang X.-P. (2016) Current Therapy of Drugs in Amyotrophic 










This article is protected by copyright. All rights reserved. 
Lysogorskaia E. V., Abramycheva N. Y., Illarioshkin S. N., Zakharova M. N. (2012) The role 
of RNA metabolism in the pathogenesis of amyotrophic lateral sclerosis. Neurochem. J. 
6, 233–238. 
Manders E. M., Stap J., Brakenhoff G. J., Driel R. van, Aten J. A. (1992) Dynamics of three-
dimensional replication patterns during the S-phase, analysed by double labelling of 
DNA and confocal microscopy. J. Cell Sci. 103 ( Pt 3), 857–62. 
Martin L. J. (2011) Mitochondrial pathobiology in ALS. J. Bioenerg. Biomembr. 43, 569–79. 
Mason S. (2017) Lactate Shuttles in Neuroenergetics—Homeostasis, Allostasis and Beyond. 
Front. Neurosci. 11, 43. 
Mattiazzi M., D’Aurelio M., Gajewski C. D., Martushova K., Kiaei M., Beal M. F., Manfredi 
G. (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in 
mitochondria of transgenic mice. J. Biol. Chem. 277, 29626–33. 
Menzies F. M., Ince P. G., Shaw P. J. (2002a) Mitochondrial involvement in amyotrophic 
lateral sclerosis. Neurochem. Int. 40, 543–51. 
Menzies F. M., Ince P. G., Shaw P. J. (2002b) Mitochondrial involvement in amyotrophic 
lateral sclerosis. Neurochem. Int. 40, 543–51. 
Milanese M., Zappettini S., Jacchetti E., Bonifacino T., Cervetto C., Usai C., Bonanno G. 
(2010) In vitro activation of GAT1 transporters expressed in spinal cord gliosomes 
stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse 
model of amyotrophic lateral sclerosis. J. Neurochem. 113, 489–501. 
Milanese M., Zappettini S., Onofri F., Musazzi L., Tardito D., Bonifacino T., Messa M., et al. 
(2011) Abnormal exocytotic release of glutamate in a mouse model of amyotrophic 










This article is protected by copyright. All rights reserved. 
Miyazaki K., Masamoto K., Morimoto N., Kurata T., Mimoto T., Obata T., Kanno I., Abe K. 
(2012) Early and progressive impairment of spinal blood flow-glucose metabolism 
coupling in motor neuron degeneration of ALS model mice. J. Cereb. Blood Flow 
Metab. 32, 456–67. 
Nagai M., Re D. B., Nagata T., Chalazonitis A., Jessell T. M., Wichterle H., Przedborski S. 
(2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively 
toxic to motor neurons. Nat. Neurosci. 10, 615–622. 
Nakamura Y., Iga K., Shibata T., Shudo M., Kataoka K. (1993) Glial plasmalemmal vesicles: 
a subcellular fraction from rat hippocampal homogenate distinct from synaptosomes. 
Glia 9, 48–56. 
Palamiuc L., Schlagowski A., Ngo S. T., Vernay A., Dirrig-Grosch S., Henriques A., 
Boutillier A.-L., et al. (2015) A metabolic switch toward lipid use in glycolytic muscle is 
an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO 
Mol. Med. 7, 526–46. 
Paluzzi S., Alloisio S., Zappettini S., Milanese M., Raiteri L., Nobile M., Bonanno G. (2007) 




 exchanger-operated exocytotic glutamate 
release triggered by mild depolarization. J. Neurochem. 103, 1196–1207. 
Papouin T., Dunphy J., Tolman M., Foley J. C., Haydon P. G. (2017) Astrocytic control of 
synaptic function. Philos. Trans. R. Soc. B Biol. Sci. 372, 20160154. 
Perea G., Navarrete M., Araque A. (2009) Tripartite synapses: astrocytes process and control 
synaptic information. Trends Neurosci. 32, 421–431. 
Peters O. M., Ghasemi M., Brown R. H. (2015) Emerging mechanisms of molecular 










This article is protected by copyright. All rights reserved. 
Philips T., Rothstein J. D. (2015) Rodent Models of Amyotrophic Lateral Sclerosis. Curr. 
Protoc. Pharmacol. 69, 5.67.1-21. 
Raiteri L., Stigliani S., Usai C., Diaspro A., Paluzzi S., Milanese M., Raiteri M., Bonanno G. 
(2008) Functional expression of release-regulating glycine transporters GLYT1 on 
GABAergic neurons and GLYT2 on astrocytes in mouse spinal cord. Neurochem. Int. 
52, 103–12. 
Raiteri M. (1983) Synaptosomes as a tool in the development of new neuroactive drugs. Rev. 
Pure Appl. Pharmacol. Sci. 4, 65–109. 
Ravera S., Bartolucci M., Calzia D., Aluigi M. G., Ramoino P., Morelli A., Panfoli I. (2013) 
Tricarboxylic acid cycle-sustained oxidative phosphorylation in isolated myelin vesicles. 
Biochimie 95, 1991–1998. 
Ravera S., Bonifacino T., Bartolucci M., Milanese M., Gallia E., Provenzano F., Cortese K., 
Panfoli I., Bonanno G. (2018) Characterization of the Mitochondrial Aerobic 
Metabolism in the Pre- and Perisynaptic Districts of the SOD1
G93A
Mouse Model of 
Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 
Rowland L. P., Shneider N. A. (2001) Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 344, 
1688–1700. 
Sasaki S., Iwata M. (1999) Ultrastructural change of synapses of Betz cells in patients with 
amyotrophic lateral sclerosis. Neurosci. Lett. 268, 29–32. 
Sasaki S., Iwata M. (2007) Mitochondrial Alterations in the Spinal Cord of Patients With 
Sporadic Amyotrophic Lateral Sclerosis. J. Neuropathol. Exp. Neurol. 66, 10–16. 
Stigliani S., Zappettini S., Raiteri L., Passalacqua M., Melloni E., Venturi C., Tacchetti C., 










This article is protected by copyright. All rights reserved. 
adult rat brain are competent for exocytotic release of glutamate. J. Neurochem. 96, 
656–68. 
Swinnen B., Robberecht W. (2014) The phenotypic variability of amyotrophic lateral 
sclerosis. Nat. Publ. Gr. doi. 
Szelechowski M., Amoedo N., Obre E., Léger C., Allard L., Bonneu M., Claverol S., et al. 
(2018) Metabolic Reprogramming in Amyotrophic Lateral Sclerosis. Sci. Rep. 8, 3953. 
Tan W., Pasinelli P., Trotti D. (2014) Role of mitochondria in mutant SOD1 linked 
amyotrophic lateral sclerosis. Biochim. Biophys. Acta - Mol. Basis Dis. 1842, 1295–
1301. 
Tefera T. W., Bartlett K., Tran S. S., Hodson M. P., Borges K. (2019) Impaired Pentose 
Phosphate Pathway in the Spinal Cord of the hSOD1G93A Mouse Model of 
Amyotrophic Lateral Sclerosis. Mol. Neurobiol., 1–12. 
Tefera T. W., Wong Y., Barkl-Luke M. E., Ngo S. T., Thomas N. K., McDonald T. S., 
Borges K. (2016) Triheptanoin Protects Motor Neurons and Delays the Onset of Motor 
Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis. PLoS One 11, 
e0161816. 
Turner M. R., Bowser R., Bruijn L., Dupuis L., Ludolph A., McGrath M., Manfredi G., et al. 
(2013) Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. 
Amyotroph. Lateral Scler. Front. Degener. 14, 19–32. 
Valbuena G. N., Tortarolo M., Bendotti C., Cantoni L., Keun H. C. (2017) Altered Metabolic 
Profiles Associate with Toxicity in SOD1G93A Astrocyte-Neuron Co-Cultures. Sci. 
Rep. 7, 50. 










This article is protected by copyright. All rights reserved. 
underappreciated opportunity? Acta Neuropathol. 135, 489–509. 
Wang Q., Yu L., Yu C.-A. (2010) Cross-talk between mitochondrial malate dehydrogenase 
and the cytochrome bc1 complex. J. Biol. Chem. 285, 10408–14. 
Whittaker V. P. (1993) Thirty years of synaptosome research. J. Neurocytol. 22, 735–42. 
Wiedemann F. R., Manfredi G., Mawrin C., Beal M. F., Schon E. A. (2002) Mitochondrial 
DNA and respiratory chain function in spinal cords of ALS patients. J. Neurochem. 80, 
616–25. 
Zhang H., Limphong P., Pieper J., Liu Q., Rodesch C. K., Christians E., Benjamin I. J. (2012) 
Glutathione-dependent reductive stress triggers mitochondrial oxidation and 




Figure 1. Scheme of glucose catabolism 
Scheme of glucose catabolism. The glycolytic pathway is presented in blue, the last step of 
lactate fermentation is presented in violet, and the Krebs cycle is presented in green. In this 
schematic, the enzymes evaluated in this article are indicated in boxes. Abbreviations: HK, 
hexokinase; PFK, phosphofructokinase; LDH, lactate dehydrogenase; CS, citrate synthase; 
MDH, malate dehydrogenase; G3P, glyceraldehyde 3-phosphate; PEP, phosphoenolpyruvate; 
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wtSOD1 and age-matched SOD1
G93A
 mice were sacrificed at postnatal days 30, 60, 90 and 
120. Purified synaptosomes and gliosomes were immunolabelled and analysed by laser 
confocal microscopy. Panels A and B show representative images triple-stained by Alexa 
Fluor 555-conjugated anti-MAP2 (blue; neuron specific marker), Alexa Fluor 488-conjugated 
anti-GFAP (green; astrocyte specific marker), and Alexa Fluor 647-conjugated anti-lactate 
dehydrogenase (LDH; red; to label the cytosol of sealed particles) purified from 90-day-old 
wtSOD1 and SOD1
G93A
 mice. The merged panels show the co-expression of MAP2, GFAP 
and LDH. Scale bar: 100 µm. Panels C and D show the percent of LDH-positive particles that 
were also positive for MAP2 or GFAP in synaptosomes and gliosomes at different ages. Data 
are presented as the mean ± s.e.m. of 3 experiments (3 independent animals) per group, each 
run in triplicate. No significant differences were found (two-way ANOVA followed by 
Bonferroni post hoc test). 
 




wtSOD1 and age-matched SOD1
G93A
 mice were sacrificed at postnatal days 30, 60, 90 and 
120. Purified synaptosomes and gliosomes were immunolabelled and analysed by laser 
confocal microscopy. Panels A and B show representative images triple-stained by Alexa 
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 mice. The merged panels show the co-expression of MAP2, GFAP 
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were also positive for MAP2 or GFAP in synaptosomes and gliosomes at the studied ages. 
Data are presented as the mean ± s.e.m. of 3 experiments (3 independent animals) per group, 
each run-in triplicate. No significant differences were found (two-way ANOVA followed by 
Bonferroni post hoc test). 
 
Figure 4. Activity of citrate synthase and malate dehydrogenase in the spinal cord 
synaptosomes, gliosomes, and tissue homogenate from wtSOD1 and SOD1
G93A
 mice 
The activity of citrate synthase (CS) and malate dehydrogenase (MDH), components of the 
Krebs cycle, was measured in the spinal cord synaptosomes, gliosomes, and tissue 
homogenate of wtSOD1 and SOD1
G93A
 mice at different stages of the disease (30, 60, 90 and 
120 days of life). The activity of CS in synaptosomes (Panel A), gliosomes (Panel B) and 
homogenate (Panel C) and the activity of MDH in synaptosomes (Panel D), gliosomes (Panel 
E) and homogenate (Panel F) are reported. For each enzyme, the data are expressed as 
international milliunits (mUI), corresponding to the nanomoles of substrate catalysed in 1 
min per mg of protein, and are presented as box-plots showing the median, quartiles (boxes) 
and range (whiskers) of 4 experiments (4 independent animals), each of which were 
performed in triplicate. * p<0.01 vs age-matched wtSOD1 mice (two-way ANOVA followed 
by Bonferroni post hoc test). 
 
Figure 5. Activity of hexokinase and phosphofructokinase in the spinal cord 
synaptosomes gliosomes and tissue homogenate of wtSOD1 and SOD1
G93A
 mice 
The activity of hexokinase (HK) and phosphofructokinase (PFK), components of the 
glycolysis pathway, was measured in the spinal cord synaptosomes, gliosomes, and tissue 
homogenate of wtSOD1 and SOD1
G93A
 mice at different stages of the disease (30, 60, 90 and 
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homogenate (Panel C) and the activity of PFK in synaptosomes (Panel D), gliosomes (Panel 
E) and homogenate (Panel F) are reported. For each enzyme, data are expressed as 
international milliunits (mUI), corresponding to the nanomoles of substrate catalysed in 1 
min per mg of protein, and are presented as box-plots showing the median, quartiles (boxes) 
and range (whiskers) of 4 experiments (4 independent animals), each of which were 
performed in triplicate* p<0.01 vs age-matched wtSOD1 mice (two-way ANOVA followed 
by Bonferroni post hoc test). 
 
Figure 6. Activity of lactate dehydrogenase in the spinal cord synaptosomes, gliosomes 
and tissue homogenate of wtSOD1 and SOD1
G93A
 mice 
The activity of lactate dehydrogenase (LDH), a marker of lactate fermentation, was measured 
in the spinal cord synaptosomes (Panel A), gliosomes (Panel B) and tissue homogenate 
(Panel C) of wtSOD1 and SOD1
G93A
 mice at different stages of the disease (30, 60, 90 and 
120 days of life). Data are expressed as international milliunits (mUI), corresponding to the 
nanomoles of substrate catalysed in 1 min per mg of protein, and are presented as box-plots 
showing the median, quartiles (boxes) and range (whiskers) 4 experiments (4 independent 
animals), each of which were performed in triplicate. * p<0.01 vs age-matched wtSOD1 mice 
(two-way ANOVA followed by Bonferroni post hoc test). 
 
Figure 7. Activity of citrate synthase and malate dehydrogenase in the motor cortex 
synaptosomes, gliosomes, and tissue homogenate of wtSOD1 and SOD1
G93A
 mice 
The activity of citrate synthase (CS) and malate dehydrogenase (MDH), components of the 
Krebs cycle, was measured in the motor cortex synaptosomes, gliosomes, and tissue 
homogenate of wtSOD1 and SOD1
G93A
 mice at different stages of the disease (30, 60, 90 and 
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(Panel B) and homogenate (Panel C) and the activity of MDH in motor cortex synaptosomes 
(Panel D), gliosomes (Panel E) and homogenate (Panels F) are reported. For each enzyme, 
data are expressed as international milliunits (mUI), corresponding to the nanomoles of 
substrate catalysed in 1 min per mg of protein, and are presented as box-plots showing the 
median, quartiles (boxes) and range (whiskers) of 4 experiments (4 independent animals), 
each of which were performed in triplicate. * p<0.01 vs age-matched wtSOD1 mice (two-way 
ANOVA followed by Bonferroni post hoc test). 
 
Figure 8. Activity of hexokinase and phosphofructokinase in the motor cortex 
synaptosomes, gliosomes, and tissue homogenate of wtSOD1 and SOD1
G93A
 mice 
The activity of hexokinase (HK) and phosphofructokinase (PFK), components of the 
glycolysis pathway, was measured in the motor cortex synaptosomes, gliosomes and tissue 
homogenate of wtSOD1 and SOD1
G93A
 mice at different stages of the disease (30, 60, 90 and 
120 days of life). The activity of HK in synaptosomes (Panel A), gliosomes (Panel B), and 
homogenate (Panel C) and the activity of PFK in synaptosomes (Panel D), gliosomes (Panel 
E) and homogenate (Panel F) are reported. For each enzyme, data are expressed as 
international milliunits (mUI), corresponding to the nanomoles of substrate catalysed in 1 
min per mg of protein, and are presented as box-plots showing the median, quartiles (boxes) 
and range (whiskers) of 4 experiments (4 independent animals), each of which were 
performed in triplicate. * p<0.01 vs age-matched wtSOD1 mice (two-way ANOVA followed 
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Figure 9. Activity of lactate dehydrogenase in the motor cortex synaptosomes, 
gliosomes, and tissue homogenate of wtSOD1 and SOD1
G93A
 mice 
The activity of lactate dehydrogenase (LDH), a marker of lactate fermentation, was measured 
in motor cortex synaptosomes (Panel A), gliosomes (Panel B) and tissue homogenate (Panel 
C) of wtSOD1 and SOD1
G93A
 mice at different stages of the disease (30, 60, 90 and 120 days 
of life). Data are expressed as international milliunits (mUI), corresponding to the nanomoles 
of substrate catalysed in 1 min per mg of protein, and are presented as box-plots showing the 
median, quartiles (boxes) and range (whiskers) of 4 experiments (4 independent animals), 
each of which was performed in triplicate. * p<0.01 vs age-matched wtSOD1 mice (two-way 
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